{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:28:52Z","timestamp":1787855332211,"version":"build-2784847793"},"reference-count":38,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.2967\/jnumed.123.266925","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T17:35:20Z","timestamp":1713461720000},"page":"845-850","source":"Crossref","is-referenced-by-count":9,"title":["Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of<sup>18<\/sup>F-FDG PET\/CT and Conventional CT Imaging"],"prefix":"10.2967","volume":"65","author":[{"given":"Rebecca","family":"Moser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisena","family":"Cala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Kiechle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie T.","family":"Behzadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Fallenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie E.","family":"Combs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai J.","family":"Borm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"2024060510401903000_65.6.845.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.8"},{"key":"2024060510401903000_65.6.845.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00201"},{"key":"2024060510401903000_65.6.845.3","doi-asserted-by":"crossref","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol."},{"key":"2024060510401903000_65.6.845.4","doi-asserted-by":"crossref","unstructured":"Ruers T Van Coevorden F Punt CJ . Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst. 2017;109:djx015.","DOI":"10.1093\/jnci\/djx015"},{"key":"2024060510401903000_65.6.845.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00818"},{"key":"2024060510401903000_65.6.845.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4853"},{"key":"2024060510401903000_65.6.845.7","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.ijrobp.2020.07.1169","article-title":"First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small-cell lung cancer: interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332) [abstract]","volume":"108","author":"Wang","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2024060510401903000_65.6.845.8","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"key":"2024060510401903000_65.6.845.9","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2022.09.008","article-title":"Final analysis of consolidative use of radiotherapy to block (CURB) oligoprogression trial: a randomized study of stereotactic body radiotherapy for oligoprogressive metastatic lung and breast cancers [abstract]","volume":"114","author":"Tsai","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2024060510401903000_65.6.845.10","doi-asserted-by":"crossref","first-page":"102462","DOI":"10.1016\/j.ctrv.2022.102462","article-title":"Oligometastatic breast cancer: dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?","volume":"110","author":"Miglietta","year":"2022","journal-title":"Cancer Treat Rev."},{"key":"2024060510401903000_65.6.845.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-022-01938-x"},{"key":"2024060510401903000_65.6.845.12","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","article-title":"A phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557) [abstract]","volume":"40","author":"Chmura","year":"2022","journal-title":"J Clin Oncol."},{"key":"2024060510401903000_65.6.845.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.07.025"},{"key":"2024060510401903000_65.6.845.14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ijc.31793","article-title":"A risk-based approach to identifying oligometastatic disease on imaging","volume":"144","author":"deSouza","year":"2019","journal-title":"Int J Cancer."},{"key":"2024060510401903000_65.6.845.15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41571-019-0220-6","article-title":"Integrated molecular and clinical staging defines the spectrum of metastatic cancer","volume":"16","author":"Pitroda","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"2024060510401903000_65.6.845.16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028650"},{"key":"2024060510401903000_65.6.845.17","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s00345-018-2609-8","article-title":"Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time","volume":"37","author":"Dhondt","year":"2019","journal-title":"World J Urol."},{"key":"2024060510401903000_65.6.845.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019"},{"key":"2024060510401903000_65.6.845.19","first-page":"72","article-title":"The value of 18F-FDG PET\/CT imaging in breast cancer staging","volume":"18","author":"Yararbas","year":"2018","journal-title":"Bosn J Basic Med Sci."},{"key":"2024060510401903000_65.6.845.20","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0030"},{"key":"2024060510401903000_65.6.845.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30718-1"},{"key":"2024060510401903000_65.6.845.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x"},{"key":"2024060510401903000_65.6.845.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.04.003"},{"key":"2024060510401903000_65.6.845.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1145-6"},{"key":"2024060510401903000_65.6.845.25","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0089"},{"key":"2024060510401903000_65.6.845.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.02.056"},{"key":"2024060510401903000_65.6.845.27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40336-021-00426-z","article-title":"Breast cancer: initial workup and staging with FDG PET\/CT","volume":"9","author":"Groheux","year":"2021","journal-title":"Clin Transl Imaging."},{"key":"2024060510401903000_65.6.845.28","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3389\/fonc.2020.01301","article-title":"Progress and future trends in PET\/CT and PET\/MRI molecular imaging approaches for breast cancer","volume":"10","author":"Ming","year":"2020","journal-title":"Front Oncol."},{"key":"2024060510401903000_65.6.845.29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs451"},{"key":"2024060510401903000_65.6.845.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2016.12.006"},{"key":"2024060510401903000_65.6.845.31","doi-asserted-by":"crossref","first-page":"e0260066","DOI":"10.1371\/journal.pone.0260066","article-title":"Diagnosis of bone metastases in breast cancer: lesion-based sensitivity of dual-time-point FDG-PET\/CT compared to low-dose CT and bone scintigraphy","volume":"16","author":"Hansen","year":"2021","journal-title":"PLoS One."},{"key":"2024060510401903000_65.6.845.32","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41416-020-01128-5","article-title":"Metastasis-directed therapy for oligometastasis and beyond","volume":"124","author":"Beckham","year":"2021","journal-title":"Br J Cancer."},{"key":"2024060510401903000_65.6.845.33","doi-asserted-by":"crossref","first-page":"929444","DOI":"10.3389\/fonc.2022.929444","article-title":"Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer","volume":"12","author":"Alberto","year":"2022","journal-title":"Front Oncol."},{"key":"2024060510401903000_65.6.845.34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.radonc.2017.08.032","article-title":"Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial","volume":"126","author":"Trovo","year":"2018","journal-title":"Radiother Oncol."},{"key":"2024060510401903000_65.6.845.35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.breast.2019.10.016","article-title":"Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: a prospective clinical trial","volume":"49","author":"David","year":"2020","journal-title":"Breast."},{"key":"2024060510401903000_65.6.845.36","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.6004\/jnccn.2020.7592","article-title":"Clinical utility of 18F-FDG PET\/CT in staging localized breast cancer before initiating preoperative systemic therapy","volume":"18","author":"Ko","year":"2020","journal-title":"J Natl Compr Canc Netw."},{"key":"2024060510401903000_65.6.845.37","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2214\/AJR.19.21373","article-title":"Identification of axillary lymph node metastasis in patients with breast cancer using dual-phase FDG PET\/CT","volume":"213","author":"Sasada","year":"2019","journal-title":"AJR."},{"key":"2024060510401903000_65.6.845.38","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.247882"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.266925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T17:42:28Z","timestamp":1717609348000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.266925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,3]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.2967\/jnumed.123.266925"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.266925","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]}}}